Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients

Acta Oncol. 2018 Oct;57(10):1414-1418. doi: 10.1080/0284186X.2018.1479069. Epub 2018 Jun 18.

Authors

Tor Magnus Smedman^{1

2}, Pål-Dag Line^{2

3}, Tormod K Guren¹, Svein Dueland¹

Affiliations

¹ a Department of Oncology , Oslo University Hospital , Oslo , Norway.
² b Institute of Clinical Medicine , University of Oslo , Oslo , Norway.
³ c Section for Transplantation Surgery, Department of Transplantation Medicine , Oslo University Hospital , Oslo , Norway.

PMID: 29912605
DOI: 10.1080/0284186X.2018.1479069

No abstract available

Publication types

Letter
Review

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Costimulatory and Inhibitory T-Cell Receptors / antagonists & inhibitors*
Graft Rejection / epidemiology*
Graft Rejection / immunology
Graft Rejection / prevention & control
Humans
Immunosuppression Therapy / adverse effects
Immunosuppression Therapy / methods*
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Incidence
Neoplasms / epidemiology
Neoplasms / immunology
Neoplasms / therapy
Organ Transplantation / adverse effects*
Transplant Recipients / statistics & numerical data
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Costimulatory and Inhibitory T-Cell Receptors
Immunosuppressive Agents